Novelion Therapeutics Inc. Common Shares
NVLN
NVLN was delisted on the 8th of October, 2019.
7 hedge funds and large institutions have $5.45M invested in Novelion Therapeutics Inc. Common Shares in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 24 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
21% less capital invested
Capital invested by funds: $6.91M → $5.45M (-$1.46M)
77% less funds holding
Funds holding: 31 → 7 (-24)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIG
EdgePoint Investment Group
Toronto,
Ontario, Canada
|
+$405K |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$146K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$1.01M |
| 2 |
HCM
Highbridge Capital Management
New York
|
-$421K |
| 3 |
Goldman Sachs
New York
|
-$150K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$87K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$61K |
NVLN Hedge Fund Activity: Q4 2019 in Review
7 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Novelion Therapeutics Inc. Common Shares (NVLN) for Q4 2019, worth a combined $5.45M — down 21% from $6.91M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of NVLN and 0 opened new positions — a net loss of 24 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was EdgePoint Investment Group, adding an estimated $405K. The largest seller was Healthcare Value Capital, exiting entirely with an estimated $1.01M sold.
- 7 institutional investors held Novelion Therapeutics Inc. Common Shares (NVLN) as of Q4 2019, down from 31 in Q3 2019.
- Funds reported $5.45M of Novelion Therapeutics Inc. Common Shares stock for Q4 2019, down 21% quarter-over-quarter.
- 0 funds opened new Novelion Therapeutics Inc. Common Shares positions in Q4 2019 and 24 closed out, a net change of -24 holders.
- The largest Novelion Therapeutics Inc. Common Shares buyer in Q4 2019 was EdgePoint Investment Group, an estimated $405K added.
- The largest Novelion Therapeutics Inc. Common Shares seller in Q4 2019 was Healthcare Value Capital, an estimated $1.01M sold.
Based on aggregated 13F filings for Q4 2019.